Literature DB >> 16628627

Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition.

Glenda G Callender1, Hugo R Rosen, Jeffrey J Roszkowski, Gretchen E Lyons, Mingli Li, Tamson Moore, Natasha Brasic, Mark D McKee, Michael I Nishimura.   

Abstract

Hepatitis C virus (HCV) has been reported to elicit B and T cell immunity in infected patients. Despite the presence of antiviral immunity, many patients develop chronic infections leading to cirrhosis, hepatocellular carcinoma, and liver failure that can require transplantation. We have previously described the presence of HLA-A2-restricted, HCV NS3-reactive cytotoxic T lymphocytes (CTL) in the blood of HLA-A2- liver transplantation patients that received an HLA-A2+ liver allograft. These T cells are analogous to the "allospecific" T cells that have been described in hematopoietic stem cell transplantation patients. It has been speculated that allospecific T cells express high-affinity T cell receptors (TCRs). To determine if our HCV-reactive T cells expressed TCRs with relatively high affinity for antigen, we identified and cloned a TCR from an allospecific HLA-A2-restricted, HCV:NS3:1406-1415-reactive CD8+ T cell clone and expressed this HCV TCR in Jurkat cells. Tetramer binding to HCV TCR-transduced Jurkat cells required CD8 expression, whereas antigen recognition did not. In conclusion, based on the reactivity of the TCR-transduced Jurkat cells, we have identified a TCR that transfers anti-HCV reactivity to alternate effectors. These data suggest this high affinity HCV-specific TCR might have potential new immunotherapic implications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16628627     DOI: 10.1002/hep.21157

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

1.  Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.

Authors:  Timothy T Spear; Yuan Wang; Kendra C Foley; David C Murray; Gina M Scurti; Patricia E Simms; Elizabeth Garrett-Mayer; Lance M Hellman; Brian M Baker; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2017-06-20       Impact factor: 6.968

2.  Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.

Authors:  Lance M Hellman; Kendra C Foley; Nishant K Singh; Jesus A Alonso; Timothy P Riley; Jason R Devlin; Cory M Ayres; Grant L J Keller; Yuting Zhang; Craig W Vander Kooi; Michael I Nishimura; Brian M Baker
Journal:  Mol Ther       Date:  2018-12-14       Impact factor: 11.454

3.  Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.

Authors:  Timothy T Spear; Timothy P Riley; Gretchen E Lyons; Glenda G Callender; Jeffrey J Roszkowski; Yuan Wang; Patricia E Simms; Gina M Scurti; Kendra C Foley; David C Murray; Lance M Hellman; Rachel H McMahan; Makio Iwashima; Elizabeth Garrett-Mayer; Hugo R Rosen; Brian M Baker; Michael I Nishimura
Journal:  J Leukoc Biol       Date:  2016-02-26       Impact factor: 4.962

4.  An Engineered T Cell Receptor Variant Realizes the Limits of Functional Binding Modes.

Authors:  Nishant K Singh; Jesus A Alonso; Daniel T Harris; Scott D Anderson; Jiaqi Ma; Lance M Hellman; Aaron M Rosenberg; Elizabeth M Kolawole; Brian D Evavold; David M Kranz; Brian M Baker
Journal:  Biochemistry       Date:  2020-10-19       Impact factor: 3.162

5.  CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression.

Authors:  Andrew Zloza; Michael C Jagoda; Gretchen E Lyons; Michael C Graves; Frederick J Kohlhapp; Jeremy A O'Sullivan; Andrew T Lacek; Michael I Nishimura; José A Guevara-Patiño
Journal:  Cancer Immunol Immunother       Date:  2010-12-31       Impact factor: 6.968

6.  Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells.

Authors:  Timothy T Spear; Yuan Wang; Thomas W Smith; Patricia E Simms; Elizabeth Garrett-Mayer; Lance M Hellman; Brian M Baker; Michael I Nishimura
Journal:  Mol Ther       Date:  2018-02-02       Impact factor: 11.454

7.  TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence.

Authors:  Timothy T Spear; Kendra C Foley; Elizabeth Garrett-Mayer; Michael I Nishimura
Journal:  J Leukoc Biol       Date:  2018-01-19       Impact factor: 4.962

8.  CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Authors:  Håkan Norell; Yi Zhang; James McCracken; Telma Martins da Palma; Aaron Lesher; Yueying Liu; Jeffrey J Roszkowski; Anquanette Temple; Glenda G Callender; Timothy Clay; Rimas Orentas; José Guevara-Patiño; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

Review 9.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

Review 10.  Human liver transplantation as a model to study hepatitis C virus pathogenesis.

Authors:  Michael G Hughes; Hugo R Rosen
Journal:  Liver Transpl       Date:  2009-11       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.